New Approaches in Nanomedicine for Ischemic Stroke

dc.contributor.affiliationUniversidade de Santiago de Compostela. Centro de Investigación en Química Biolóxica e Materiais Molecularesgl
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Física de Partículasgl
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Química Inorgánicagl
dc.contributor.authorCorrea Paz, Clara
dc.contributor.authorSilva Candal, Andrés da
dc.contributor.authorPolo Tobajas, Ester
dc.contributor.authorParcq, Jerome
dc.contributor.authorVivien, Denis
dc.contributor.authorMaysinger, Dusica
dc.contributor.authorPelaz García, Beatriz
dc.contributor.authorCampos Pérez, Francisco
dc.date.accessioned2021-05-21T11:53:26Z
dc.date.available2021-05-21T11:53:26Z
dc.date.issued2021
dc.description.abstractIschemic stroke, caused by the interruption of blood flow to the brain and subsequent neuronal death, represents one of the main causes of disability in developed countries. Therapeutic methods such as recanalization approaches, neuroprotective drugs, or recovery strategies have been widely developed to improve the patient’s outcome; however, important limitations such as a narrow therapeutic window, the ability to reach brain targets, or drug side effects constitute some of the main aspects that limit the clinical applicability of the current treatments. Nanotechnology has emerged as a promising tool to overcome many of these drug limitations and improve the efficacy of treatments for neurological diseases such as stroke. The use of nanoparticles as a contrast agent or as drug carriers to a specific target are some of the most common approaches developed in nanomedicine for stroke. Throughout this review, we have summarized our experience of using nanotechnology tools for the study of stroke and the search for novel therapiesgl
dc.description.peerreviewedSIgl
dc.description.sponsorshipThis project was supported by the FRQS, ISCIII (AC19/00031 and AC20/00041), and ANR under the framework of EuroNanoMed III_2020 (PLATMED_project); the European Union program FEDER and the European Regional Development Fund–ERDF; and the Xunta de Galicia (IN607D2020/03 and ED431G2019/03). E.P. and B.P acknowledge the AEI grants (PID2019-111218RB-I00 and RyC-2017-23457). Finally, F.C. thanks the ISCIII and Miguel Servet program (CPII19/00020)gl
dc.identifier.citationPharmaceutics 2021, 13(5), 757; https://doi.org/10.3390/pharmaceutics13050757gl
dc.identifier.doi10.3390/pharmaceutics13050757
dc.identifier.essn1999-4923
dc.identifier.urihttp://hdl.handle.net/10347/26254
dc.language.isoenggl
dc.publisherMDPIgl
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RYC-2017-23457/ES
dc.relation.publisherversionhttps://doi.org/10.3390/pharmaceutics13050757gl
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)gl
dc.rightsAtribución 4.0 Internacional
dc.rights.accessRightsopen accessgl
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCell trackinggl
dc.subjectDiagnosisgl
dc.subjectDrug carriersgl
dc.subjectDrug control releasegl
dc.subjectNanomedicinegl
dc.subjectNeuroprotectiongl
dc.subjectRecoverygl
dc.subjectStrokegl
dc.subjectTissue plasminogen activatorgl
dc.titleNew Approaches in Nanomedicine for Ischemic Strokegl
dc.typejournal articlegl
dc.type.hasVersionVoRgl
dspace.entity.typePublication
relation.isAuthorOfPublication8b9beb32-7cfc-4c41-871e-f0960dcb60e3
relation.isAuthorOfPublicationae6cfd5f-90ba-47e5-9d34-20c3361b7df3
relation.isAuthorOfPublication.latestForDiscovery8b9beb32-7cfc-4c41-871e-f0960dcb60e3

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2021_pharmaceutics_correa_new.pdf
Size:
6.26 MB
Format:
Adobe Portable Document Format
Description: